Anglo-Swedish drugmaker AstraZeneca raised its full year sales and profit forecast on Thursday (Jul 25) after beating analyst expectations for second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines.
Sales in AstraZeneca’s top business, oncology, grew 19 per cent at constant currency rates to US$5.33 billion and accounted for 41 per cent of the total, while its rare disease and heart and kidney disease divisions also each raked in double-digit growth.
Second-quarter profit though was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said.
The shares slipped 3.6 per cent by 0830 GMT after gains of about 14 per cent so far this year.
British rival GSK’s shares are up 4.1 per cent this year and Swiss drugmaker Roche is up 11 per cent this year, compared with the STOXX 600 Index gains of 7 per cent.
AstraZeneca expects both 2024 revenue and core earnings per share to increase by a mid-teens percentage at constant currency rates, it said. It had previously expected revenue and profit to increase by a low double-digit to low-teens percentage.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
The UK’s most valuable company in terms of its market capitalisation of US$243.89 billion has evolved significantly since CEO Pascal Soriot took over 12 years ago. New technologies such as antibody-drug conjugates are making up a rising proportion of its future cancer therapies.
The sales outlook reflects how the company has moved beyond the Covid vaccine, its best-selling product at the height of the pandemic in 2021, thanks to its roster of cancer therapies and a strong pipeline, including new treatments in other disease areas by the end of the decade.
“In the year to date we have continued to make encouraging progress with several disruptive technologies … all of which have the potential to drive our growth beyond 2030,” CEO Soriot said in a statement.
At its investor day in May, the company announced it aimed to grow revenue by about 75 per cent to US$80 billion by 2030, citing the expected launch of 20 new medicines and growth in its cancer, biopharmaceuticals and rare disease portfolio.
The company has been investing in building its pipeline and marketing new launches. In May, AstraZeneca said that a plant in Qingdao, China, will help it build a distinct local supply chain to serve the Chinese market, its second largest globally.
Operating expenses in the quarter were 14 per cent higher at US$6.74 billion.
Total revenue rose 17 per cent on a constant-currency basis to US$12.94 billion for the three months ended June, while core earnings came in at US$1.98 per share, compared with analysts’ average expectation of US$12.6 billion and US$1.98 per share, respectively, according to a company-compiled consensus. REUTERS
